- Home
- ZVSA vs AEMD Comparison
ZVSA vs AEMD Comparison
Compare ZVSA & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- AEMD
- Stock Information
- Founded
- ZVSA 2014
- AEMD 1984
- Country
- ZVSA United States
- AEMD United States
- Employees
- ZVSA N/A
- AEMD N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- AEMD Medical/Dental Instruments
- Sector
- ZVSA Health Care
- AEMD Health Care
- Exchange
- ZVSA Nasdaq
- AEMD Nasdaq
- Market Cap
- ZVSA 2.8M
- AEMD 2.1M
- IPO Year
- ZVSA N/A
- AEMD N/A
- Fundamental
- Price
- ZVSA $2.51
- AEMD $0.35
- Analyst Decision
- ZVSA Strong Buy
- AEMD Strong Buy
- Analyst Count
- ZVSA 1
- AEMD 1
- Target Price
- ZVSA $240.00
- AEMD $7.00
- AVG Volume (30 Days)
- ZVSA 93.2K
- AEMD 3.6M
- Earning Date
- ZVSA 08-09-2024
- AEMD 08-14-2024
- Dividend Yield
- ZVSA N/A
- AEMD N/A
- EPS Growth
- ZVSA N/A
- AEMD N/A
- EPS
- ZVSA N/A
- AEMD N/A
- Revenue
- ZVSA N/A
- AEMD N/A
- Revenue This Year
- ZVSA N/A
- AEMD N/A
- Revenue Next Year
- ZVSA N/A
- AEMD N/A
- P/E Ratio
- ZVSA N/A
- AEMD N/A
- Revenue Growth
- ZVSA N/A
- AEMD N/A
- 52 Week Low
- ZVSA $2.50
- AEMD $0.24
- 52 Week High
- ZVSA $79.80
- AEMD $2.90
- Technical
- Relative Strength Index (RSI)
- ZVSA 38.18
- AEMD 43.91
- Support Level
- ZVSA $2.71
- AEMD $0.33
- Resistance Level
- ZVSA $2.89
- AEMD $0.40
- Average True Range (ATR)
- ZVSA 0.37
- AEMD 0.10
- MACD
- ZVSA 0.00
- AEMD -0.01
- Stochastic Oscillator
- ZVSA 0.00
- AEMD 5.06
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical technology company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.